Lewis E Johnson

US Patent:

42935687, Oct 6, 1981

Filed:

Apr 1, 1980

Appl. No.:

6/136297

Inventors:

Emil Wirostko - Paramus NJ
Lewis A. Johnson - New York NY

International Classification:

A61K 31135
A61K 3110

US Classification:

424330

Abstract:

Sterile aqueous humor from patients afflicted with the disease endogenous uveitis contains a previously unreported pathogenic microorganism, Micromyces intracellularis, which also has been found in tissue specimens from other diseases. When inoculated into an animal model (e. g. , a mouse), the microorganism produces both chronic eye and systemic disease in addition to accelerated mortality and occasional psychotic animal behavior, metabolic distrubances, and neuro-muscular disorders, depending on the mode of inoculation. The animal model therefore provides the basis for a screening process to evaluate chemotherapeutic agents in the treatment of human disease. Using this animal model, a significant decrease in mortality associated with the introduction of Micromyces intracellularis is achieved by the application to the animal model of the chemotherapeutic agents d-2,2'-(ethylenediimino)-di-1-butanol, 4,4'sulfonyldianiline, and 3[[(4-methyl-1-piperazinyl)-imino]-methyl]-rifamycin SV. These agents are therefore effective in the treatment of diseases having as their etiological agent Micromyces intracellularis, and are particularly useful in the chemotherapy of endogenous uveitis, conjunctivitis and kerato-conjunctivitis.

US Patent:

42206570, Sep 2, 1980

Filed:

Aug 11, 1978

Appl. No.:

5/932904

Inventors:

Lewis A. Johnson - New York NY
Emil Wirostko - Paramus NJ

International Classification:

A61K 3134
C12K 100

US Classification:

424285

Abstract:

Sterile aqueous humor from patients afflicted with the disease endogenous uveitis contains a previously unreported pathogenic microorganism, Micromyces intracellularis, which also has been found in tissue specimens from other diseases. When inoculated into an animal model (e. g. , a mouse), the microorganism produces both chronic eye and systemic disease in addition to accelerated mortality and occasional psychotic animal behavior, metabolic disturbances, and neuro-muscular disorders, depending on the mode of inoculation. The animal model therefore provides the basis for a screening process to evaulate chemotherapeutic agents in the treatment of human disease. Using this animal model, a significant decrease in mortality associated with the introduction of Micromyces intracellularis is achieved by the application to the animal model of the chemotherapeutic agents d-2,2'-(ethylenediimino)-di-1-butanol, 4,4'sufonyldianiline, and 3[[(4-methyl-1-piperazinyl)-imino]methyl]-rifamycin SV. These agents are therefore effective in the treatment of diseases having as their etiological agent Micromyces intracellularis, and are particularly useful in the chemotherapy of endogenous uveitis, conjunctivitis and kerato-conjunctivitis.

US Patent:

42923271, Sep 29, 1981

Filed:

Mar 31, 1980

Appl. No.:

6/135887

Inventors:

Lewis A. Johnson - New York NY
Emil Wirostko - Paramus NJ

International Classification:

A61K 3113

US Classification:

424325

Abstract:

Sterile aqueous humor from patients afflicted with the disease endogenous uveitis contains a previously unreported pathogenic microorganism, Micromyces intracellularis, which also has been found in tissue specimens from other diseases. When inoculated into an animal model (e. g. , a mouse), the microorganism produces both chronic eye and systemic disease in addition to accelerated mortality and occasional psychotic animal behavior, metabolic disturbances, and neuro-muscular disorders, depending on the mode of inoculation. The animal model therefore provides the basis for a screening process to evaluate chemotherapeutic agents in the treatment of human disease. Using this animal model, a significant decrease in mortality associated with the introduction of Micromyces intracellularis is achieved by the application to the animal model of the chemotherapeutic agents d-2,2'-(ethylenediimino)-di-1-butanol, 4,4'sulfonyldianiline, and 3[[(4-methyl-1-piperazinyl)-imino]-methyl]-rifamycin SV. These agents are therefore effective in the treatment of diseases having as their etiological agent Micromyces intracellularis, and are particularly useful in the chemotherapy of endogenous uveitis, conjunctivitis and kerato-conjunctivitis.

US Patent:

44683987, Aug 28, 1984

Filed:

Oct 21, 1981

Appl. No.:

6/313269

Inventors:

Lewis A. Johnson - New York NY
Emil Wirostko - Paramus NJ

International Classification:

A61K 31495

US Classification:

424250

Abstract:

Sterile aqueous humor from patients afflicted with the disease endogenous uveitis contains a previously unreported pathogenic microorganism, Micromyces intracellularis, which also has been found in tissue specimens from other diseases. When inoculated into an animal model (e. g. , a mouse), the microorganism produces both chronic eye and systemic disease in addition to accelerated mortality and occasional psychotic animal behavior, metabolic disturbances, and neuro-muscular disorders, depending on the mode of inoculation. The animal model therefore provides the basis for a screening process to evaluate chemotherapeutic agents in the treatment of human disease. Using this animal model, a significant decrease in mortality associated with the introduction of Micromyces intracellularis is achieved by the application to the animal model of the chemotherapeutic agents d-2,2'-(ethylenediimino)-di-1-butanol, 4,4'sulfonyldianiline, and 3[[(4-methyl-1-piperazinyl)-imino]methyl]-rifamycin SV. These agents are therefore effective in the treatment of diseases having as their etiological agent Micromyces intracellularis, the last of the three being particularly useful in the treatment of rheumatoid arthritis.